Skip to main content

Table 2 LMS-QoL values and changes from baseline.

From: Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study

Time points and periods

Parameters

Total group

Treatment-naive

group

Pre-treated

group

Baseline (B)

Mean (SD)

19.51 (4.19)

19.54 (4.26)

19.47 (4.12)

 

Median

19.00

20.00

19.00

 

95% CI (mean)

18.92; 20.10

18.72; 20.36

18.61; 20.33

Month 6 (M6)

Mean (SD)

20.95 (4.63)

21.35 (4.63)

20.48 (4.61)

 

Median

21.00

22.00

21.00

 

95% CI (mean)

20.26; 21.65

20.40; 22.31

19.45; 21.51

Month 12 (M12)

Mean (SD)

20.94 (4.69)

21.73 (4.76)

19.98 (4.43)

 

Median

21.00

21.50

20.00

 

95% CI (mean)

20.25; 21.63

20.78; 22.69

19.00; 20.96

Change B to M6

Mean (SD)

1.41 (3.97)*

1.90 (4.08)*

0.82 (3.77)

 

Median

1.00

1.00

1.00

 

95% CI (mean)

0.81; 2.00

1.06; 2.74

-0.02; 1.67

Change B to M12

Mean (SD)

1.33 (4.24)*

2.10 (4.56)*

0.40 (3.64)

 

Median

1.00

1.00

1.00

 

95% CI (mean)

0.70; 1.96

1.19; 3.02

-0.41; 1.20

  1. SD, standard deviation; CI, confidence interval; *, p < 0.001. Differences between groups were not statistically tested.